Aveeno is one of the most recognized skincare brands in the world, known for its use of natural ingredients like oats and soy. Many people wonder who owns Aveeno and how it became a household name. The answer lies in its long history, corporate ownership, and the companies that shaped its growth.
Key Takeaways
- Aveeno is owned by Kenvue Inc., the consumer health company that was spun off from Johnson & Johnson in 2023.
- Kenvue is the parent company, managing Aveeno along with other major brands like Neutrogena, Listerine, and Tylenol.
- Institutional investors are the main shareholders of Kenvue, with firms such as Vanguard Group, BlackRock, and State Street holding the largest stakes.
- No single individual or family owns Aveeno, as it is part of Kenvue’s publicly traded structure, where ownership is divided among institutional, retail, and insider investors.
Aveeno Company Profile
Aveeno is an American skincare and haircare brand. It emphasizes the use of natural ingredients like colloidal oats and plant extracts. It operates globally. In 2025, Aveeno is part of the Kenvue consumer health portfolio.
The brand’s name is drawn from Avena sativa, the scientific name for oats, which reflects its core ingredient philosophy. Its products include moisturizers, facial cleansers, sunscreens, baby skin care, and hair treatments. It is known for catering to sensitive skin, eczema, dryness, and dermatological concerns.
Its online presence remains strong, and the brand has committed to sustainability goals in 2025, such as increasing recyclable packaging and reducing waste. Over 80 % of Aveeno bottles are now recyclable. The brand aims for 100 % of its packaging to be recyclable, reusable, or compostable by 2025.
In 2025, as part of Kenvue’s strategy, Aveeno continues to benefit from shared research, global supply chain scale, and brand marketing resources.
Aveeno Founders
Aveeno was founded in 1945 by brothers Albert Musher and Sidney Musher. They began working alongside scientists from the Mayo Clinic to study the therapeutic properties of finely milled oats and colloidal oatmeal on dry and irritated skin. Their work laid the scientific and clinical basis of what would become Aveeno’s signature formulations.
The Mushers’ original aim was to develop formulations that balanced the power of nature with rigorous scientific testing. They introduced Aveeno’s first product, the Soothing Bath Treatment, which remains a foundational product in the brand’s history.
Major Milestones
- 1945 – Aveeno is founded by Albert and Sidney Musher in collaboration with Mayo Clinic scientists. The first product, the Soothing Bath Treatment, is introduced using colloidal oatmeal.
- 1950s – The brand gains recognition among dermatologists and pharmacists as a trusted option for skin irritation and dryness.
- 1975 – Aveeno introduces its first line of therapeutic moisturizers, expanding beyond bath treatments.
- 1989 – Parent entity Rydelle Laboratories officially adopts the Aveeno name for branding and marketing, marking the start of stronger consumer recognition.
- 1991 – Expansion into baby skincare begins with early formulations designed for sensitive infant skin.
- 1999 – Johnson & Johnson acquires Aveeno, integrating it into its consumer health division. This acquisition brings Aveeno into global markets.
- 2001 – Launch of Aveeno Baby products, which quickly become one of the top-selling baby care lines.
- 2004 – Introduction of the Positively Radiant collection with “Active Soy” technology, a major milestone in facial skincare.
- 2005–2007 – Rapid expansion into facial skincare with launches of the Clear Complexion (2005), Ultra Calming (2006), and Anti-Aging (2007) collections.
- 2011 – Aveeno partners with Jennifer Aniston as a brand ambassador, elevating global awareness.
- 2013 – The brand enters the natural haircare segment with shampoos and conditioners infused with oat-based ingredients.
- 2015 – Aveeno Baby becomes a global brand available in multiple international markets.
- 2017 – Aveeno launches its first line of eczema therapy products, expanding into dermatology-recommended solutions.
- 2021 – Johnson & Johnson recalls certain Aveeno aerosol sunscreens due to benzene concerns, prompting a renewed focus on safety and product transparency.
- 2023 – Johnson & Johnson spins off its consumer health division into Kenvue Inc. Aveeno officially becomes part of Kenvue’s brand portfolio.
- 2024 – Aveeno strengthens its sustainability push, making over 80% of its bottles recyclable and aiming for 100% by 2025.
- 2025 – Kenvue, Aveeno’s parent company, debuts on the Fortune 500 list at rank 281, reflecting its $15.5 billion revenue, with Aveeno as one of its key skincare contributors.
Who Owns Aveeno?
Aveeno is owned by Kenvue Inc., a standalone consumer health company. Aveeno is one of Kenvue’s flagship skincare brands. Kenvue itself was formed through a corporate spin-off from Johnson & Johnson. Before that, Aveeno was under Johnson & Johnson’s consumer health division.
When Kenvue initially launched, Johnson & Johnson retained a major ownership stake. Over time, Kenvue completed its separation and became fully independent.
As of August 2023, J&J held about 9.5 % of Kenvue’s shares following an exchange offer.
Kenvue is publicly traded under the ticker “KVUE.” It now has its own board, leadership, and governance structure.
Parent Company: Kenvue Inc.
Kenvue Inc. is the parent company that currently owns and operates Aveeno. It was formed as a spin-off from Johnson & Johnson’s consumer health division.
Kenvue was incorporated in Delaware in February 2022 as part of the planned separation of Johnson & Johnson’s consumer health business. The name “Kenvue” was publicly announced in September 2022. The intent was to allow J&J to focus on its pharmaceutical and medical device lines, and give the consumer health business its own more agile identity.
In May 2023, Kenvue conducted its initial public offering (IPO), listing its shares on the New York Stock Exchange under the ticker symbol KVUE. At that time, Johnson & Johnson retained the majority of shares. Over the following months, J&J engaged in a share exchange, which reduced its ownership stake.
By August 2023, the spin-off process was completed, and Kenvue declared itself fully independent—though J&J still held about 9.5 % of Kenvue’s shares following the exchange.
Kenvue is governed by its own board, independent of J&J’s direct management. Its executive decisions now affect Aveeno and other brands directly.
In 2025, the company undertook a strategic review of its operations and brand portfolio, especially in its skin health and beauty division, where Aveeno sits. Under pressure from activist investors, Kenvue began assessing whether to divest or restructure certain assets.
Also in 2025, Kenvue’s CEO, Thibaut Mongon, departed, and Kirk Perry was appointed interim CEO. That change underscores the growing complexity and expectations placed on Kenvue as it seeks to deliver profitability and growth in a competitive consumer health market.
Acquisition History and Transition
Aveeno was not originally created within Kenvue. Its history of acquisition is key to understanding how it came under current ownership:
- Aveeno began as part of Rydelle Laboratories, a division of S. C. Johnson & Son. Over time, Rydelle dropped its name and aligned all its lines under the Aveeno brand.
- In 1999, Johnson & Johnson acquired Aveeno, bringing it into one of the world’s largest health and consumer product organizations. That acquisition gave Aveeno access to global distribution, research, and marketing resources.
- In November 2021, Johnson & Johnson announced plans to spin off its consumer health business. This included Aveeno and other brands.
- The new entity, Kenvue, was named in September 2022, and in May 2023, it held its IPO, offering shares to the public while J&J retained a majority stake initially.
- In August 2023, Kenvue and Johnson & Johnson completed a share exchange that further separated their operations, leaving J&J with roughly 9.5 % ownership in Kenvue.
- By that point, Kenvue became fully independent, governing its brands, including Aveeno, under its own corporate structure.
Governance and Shareholder Structure
As a public company, Kenvue’s ownership is divided among institutional investors, Johnson & Johnson’s residual stake, and smaller shareholders. Because Aveeno is a brand under Kenvue, Aveeno itself does not maintain a separate equity structure.
Some important points about governance and shareholder control:
- Johnson & Johnson, while no longer the parent, remains the largest minority stakeholder in Kenvue, which gives it influence but not controlling power.
- Major institutional investors (such as Vanguard, BlackRock, State Street, and Fidelity) hold sizable blocks of shares in Kenvue. These firms can influence board votes, executive compensation, and strategic decisions.
- In 2025, activist investor Starboard Value gained attention when it pushed for board changes at Kenvue. As part of a settlement, Kenvue appointed three new directors (including Starboard’s CEO). This demonstrates that external shareholders are actively participating in corporate governance.
- Kenvue’s board structure, audit committees, and executive team now operate independently of Johnson & Johnson. Aveeno’s strategy and operations are overseen by the brand management team under Kenvue’s corporate umbrella.
Strategic Challenges and Brand Decisions
Given its position under Kenvue, Aveeno’s future direction is influenced by broader portfolio decisions:
- In 2025, Kenvue began a strategic review of its skin health and beauty segment (which includes Aveeno). The company is considering selling off some underperforming or noncore brands, though Aveeno is not on the divestiture list.
- Kenvue’s decision to keep Aveeno and Neutrogena reflects their strong market standing and brand equity.
- The activism by investors and board shakeups mean that Aveeno’s direction (innovation, marketing investments, expansion into new markets) may shift depending on Kenvue’s evolving strategy.
Who Manufactures Aveeno Products?
Aveeno’s products are manufactured in a mix of internal plants and contract facilities. Major in-house manufacturing sites relevant to Aveeno include Lititz (Pennsylvania, USA), Shanghai (China), and Bangkok (Thailand). The brand also depends significantly on external manufacturers for flexibility and local market compliance.
In-House Facilities
Below is a list of the major in-house facilities where Aveeno and other Kenvue products are manufactured:
Lititz, Pennsylvania, USA
This is one of Kenvue’s major in-house plants. It is strategically important for Aveeno, as this facility produces Skin Health & Beauty and Essential Health products. Aveeno’s lotions, body washes, and other personal care items are manufactured here alongside other brands. Lititz benefits from proximity to raw material suppliers, R&D sites, and U.S. regulatory oversight.
Shanghai, China
Kenvue has an in-house facility in Shanghai that produces Self Care and Essential Health products. Although the facility is not exclusively for Aveeno, some Aveeno lines (especially those intended for the Asia-Pacific markets) are produced here. This helps serve demand in the region and reduce shipping time and cost.
Bangkok, Thailand
The Bangkok facility is another in-house site. It handles significant production capacity for Skin Health & Beauty products. Aveeno products for Southeast Asia and nearby markets may be produced here. This plant has been noted for its sustainability practices, earning recognition (e.g., “WEF Lighthouse” status) for its operations.
External & Contract Manufacturing
Aveeno (via Kenvue) also uses a broad network of external manufacturing partners. These are third-party manufacturers that produce either part of Aveeno’s product lines under contract. Some important points:
- In recent reports, about 44% of Kenvue’s production volume is supplied by external manufacturers; the rest comes from in-house plants. This proportion gives the company flexibility to scale, respond to demand spikes, and avoid over-investing in capacity before it is needed.
- Contract manufacturers allow Aveeno to localize production in markets where regulatory, logistical, or cost constraints make local in-house plants less efficient. For example, for certain products sold in Canada, Korea, or Europe, external manufacturers may produce them under Aveeno’s oversight.
Other Facility Details
- Quality & Regulatory Compliance: All Aveeno-related manufacturing plants (both in-house and third-party) must follow Good Manufacturing Practices (GMP). They also must comply with local cosmetic, health, and safety regulations. Given Aveeno’s positioning (sensitive skin, dermatologist recommended), there is strong emphasis on quality control, ingredient safety, and clean labeling.
- Ingredient Sourcing & Specialization: Some facilities are specialized in handling Aveeno’s signature ingredients (e.g., oat derivatives, colloidal oatmeal). Research & Development (R&D) arms tied to manufacturing help ensure that oat extraction and processing meet strict safety and efficacy standards.
- Sustainability & Efficiency: Several of the mentioned sites (e.g., Bangkok) have earned sustainability recognitions. This implies investments in energy efficiency, waste reduction, and other environmental practices, which impact how products are manufactured and packaged.
Who is the CEO of Aveeno?
Aveeno is a brand under Kenvue Inc., it does not have a separate, standalone CEO. The person serving as Kenvue’s CEO leads strategic, operational, and brand decisions across the portfolio, which includes Aveeno. The CEO is responsible for setting vision, resource allocation, major investments, and performance targets for Aveeno along with other brands.
Current CEO: Kirk Perry
As of September 2025, the CEO position at Kenvue is held on an interim basis by Kirk Perry. The transition took place on July 14, 2025, when the Board appointed Perry as interim CEO following the departure of Thibaut Mongon.
Perry was already a member of Kenvue’s Board (since December 2024) before being elevated to this role.
His mandate includes guiding Kenvue while the company undertakes a strategic review of its brand portfolio, operations, and long-term direction.
Perry brings over 30 years of experience in global consumer packaged goods, technology, and business transformation. Before joining Kenvue, he served as CEO of Circana, a company specializing in consumer and retail analytics, following his role at IRI (Information Resources).
He also held senior marketing and management roles earlier in his career, including at Procter & Gamble.
As interim CEO, Perry’s tasks include overseeing current performance, shaping the coming CEO search, and positioning brands like Aveeno in a changing competitive environment. He is expected to work with the Board’s Strategic Review Committee, which is assessing possible structural changes.
Former CEO: Thibaut Mongon
Prior to this change, Thibaut Mongon served as the CEO of Kenvue from the time of its spin-off in 2023 until July 2025. Mongon came with strong credentials from Johnson & Johnson, where he led consumer health operations.
Under Mongon’s leadership, Kenvue worked to establish its identity as an independent consumer health company, manage the separation process from J&J, and stabilize operations for its brands including Aveeno.
His tenure was marked by challenges such as slipping sales in certain divisions, pressure from activist investors, and the need to streamline operations.
In July 2025, Mongon stepped down from both the CEO position and the Board.
Decision-Making Structure
Kirk Perry, as interim CEO, is not expected to remain permanently; the Board has engaged the executive search firm Heidrick & Struggles to find a full-time CEO.
During this transition, a Strategic Review Committee is leading the evaluation of Kenvue’s brand portfolio, operational efficiency, and possible restructuring. This committee is advising or working with external firms to explore alternatives.
Decisions made during the interim period will affect resource allocation, innovation priorities, and the role of Aveeno within the portfolio.
The structure under the CEO includes brand presidents, product line leaders, and regional managers. For Aveeno, brand leadership will report through Kenvue’s skincare or beauty division to the interim CEO. In effect, while Aveeno is a major brand, its decision-making power is anchored in Kenvue’s executive and operating hierarchy.
Implications for Aveeno
This change in the CEO role can impact Aveeno in several ways. The choice of a new permanent CEO could shift strategic emphasis (growth vs. cost discipline). During the interim phase, Aveeno must maintain product development, marketing investment, and market position even as parent leadership is in flux.
Because Aveeno is among Kenvue’s stronger skincare brands, it is unlikely to be divested. However, its competitive trajectory, innovation funding, or geographic expansion may evolve under new leadership.
Aveeno Annual Revenue and Net Worth
Aveeno remains one of the most recognized brands in the global skin-care and personal-care industry. As of September 2025, it generated $1.35 billion in revenue and has an estimated net worth of around $3 billion.
This positions Aveeno among Kenvue’s strongest performers in the Skin Health & Beauty division, alongside Neutrogena and Clean & Clear.
Below is an overview of the historical revenue and net worth of Aveeno from 2015-25:
| Year | Estimated Revenue (USD) | Estimated Brand Net Worth (USD) | Key Notes |
|---|---|---|---|
| 2015 | $850 million | $1.6 billion | Strong U.S. sales, baby-care line gaining traction |
| 2016 | $900 million | $1.7 billion | Expansion in moisturizers and sun-care boosted growth |
| 2017 | $950 million | $1.8 billion | Aveeno Baby became a category leader in North America |
| 2018 | $1.0 billion | $2.0 billion | Cross-border expansion in Asia-Pacific |
| 2019 | $1.05 billion | $2.1 billion | Increased e-commerce presence drove sales |
| 2020 | $1.2 billion | $2.3 billion | Pandemic-driven demand for skin-care and hygiene products |
| 2021 | $1.3 billion | $2.5 billion | Continued strong demand in self-care and natural skin solutions |
| 2022 | $1.25 billion | $2.6 billion | Inflation and supply chain pressures slightly slowed growth |
| 2023 | $1.28 billion | $2.7 billion | Kenvue spin-off gave brand renewed market visibility |
| 2024 | $1.3 billion | $2.9 billion | Stable sales across skin-care and baby-care categories |
| 2025 | $1.35 billion (est.) | $3.0 billion (est.) | Growth driven by emerging markets and product innovations |
Revenue Contribution
The Skin Health & Beauty segment brought in roughly $4.2 billion in 2024, making it one of Kenvue’s largest business categories. Aveeno accounts for a significant share of this revenue, particularly in North America, where the brand has a stronghold in the moisturizers, cleansers, and baby-care categories. Its product diversification—from daily moisturizers to therapeutic solutions for sensitive skin—helps ensure consistent sales despite market fluctuations.
Aveeno’s strong reputation for dermatologically tested, oat-based formulations has enabled the brand to expand internationally. In markets such as Asia-Pacific, sales have been rising steadily as demand for “science-backed natural” skincare continues to grow. This regional diversification strengthens Aveeno’s revenue base and cushions it against slower growth in mature markets.
Net Worth
In terms of brand equity, Aveeno holds a substantial position within the beauty and personal-care market. Industry experts estimate its brand value at several billion dollars, with conservative estimates placing it in the $3 billion range in terms of net worth as of September 2025.
This valuation reflects not just current revenue streams but also the long-term strength of its trademarks, global consumer loyalty, and strong placement in pharmacies, supermarkets, and e-commerce channels.
The net worth of Aveeno in a brand sense is closely tied to how much revenue it consistently generates and the strategic value it brings to Kenvue’s portfolio. Given its decades-long heritage, widespread trust among dermatologists, and established baby-care line, Aveeno is viewed as a cornerstone brand that supports Kenvue’s broader growth ambitions.
Looking ahead, Aveeno’s revenue growth is expected to benefit from rising demand for natural and therapeutic skincare products, as well as expanded distribution in emerging markets. With increasing global awareness of sensitive-skin solutions, Aveeno is positioned to strengthen its financial footprint in the coming years.
Brands Owned by Aveeno
As of 2025, Aveeno operates a broad portfolio of product families and sub-brands that function as separate consumer-facing entities. From Aveeno Baby to Aveeno Calm + Restore, the company has built a versatile brand ecosystem covering everyday hydration, infant care, acne solutions, therapeutic skincare, and even hair care.
Below is a list of the major brands owned by Aveeno as of 2025:
| Brand/Sub-Brand | Category | Key Products | Core Ingredients/Focus | Market Position |
|---|---|---|---|---|
| Aveeno Skin Care | Facial & Body Care | Moisturizers, cleansers, body lotions, hand creams | Colloidal oatmeal, oat extracts | Flagship line, largest revenue driver, trusted for sensitive/dry skin |
| Aveeno Baby | Infant Care | Baby lotions, shampoos, washes, diaper rash creams | Gentle oat formulations, chemical-free | Market leader in baby skincare across North America & Europe |
| Aveeno Baby Dermexa | Specialized Infant Care | Eczema creams, therapeutic washes | Colloidal oatmeal, ceramides | Clinically positioned sub-line for eczema-prone baby skin |
| Aveeno Positively Radiant | Radiance & Tone Care | Cleansers, scrubs, moisturizers, night creams | Soy complex, brightening agents | Popular consumer line, strong presence in U.S. & Asia |
| Aveeno Calm + Restore | Sensitive Skin Care | Moisturizers, serums, mists | Oat extracts, feverfew | Designed for ultra-sensitive skin, dermatologically recommended |
| Aveeno Clear Complexion | Acne & Blemish Care | Cleansers, toners, moisturizers | Salicylic acid, soy | Targets acne-prone skin while improving skin tone |
| Aveeno Daily Moisturizing | Everyday Body Care | Lotions, creams, body washes | Oat-based hydration | One of Aveeno’s longest-running and best-selling lines |
| Aveeno Therapeutic Line | Clinical/OTC Care | Eczema therapy creams, anti-itch lotions, foot/hand treatments | Colloidal oatmeal, barrier-protective formulas | Recommended by dermatologists, bridges skincare & medical use |
| Aveeno Sun Care | Sun Protection | Sunscreens for adults & children | Mineral-based SPF, oat-infused | Sensitive-skin-friendly sun protection products |
| Aveeno Hair Care (Active Naturals) | Hair & Scalp Care | Shampoos, conditioners, scalp treatments | Oat extract, natural botanicals | Addresses scalp dryness, dandruff, and sensitive scalp conditions |
| Aveeno Men’s Care | Men’s Skincare | Face washes, aftershaves, moisturizers | Oat extracts, soothing agents | Smaller but growing line targeting men with sensitive skin |
Aveeno Skin Care
Aveeno’s flagship product line, Skin Care, focuses on dermatologically tested moisturizers, cleansers, and treatments. It is built around the brand’s signature colloidal oatmeal and oat-based formulations, designed for sensitive and dry skin. This segment covers facial cleansers, daily moisturizers, hand creams, and body lotions. As of 2025, it is Aveeno’s largest line, generating the majority of its global sales.
Aveeno Baby
Aveeno Baby is one of the most trusted sub-brands for infant skincare. It includes baby lotions, shampoos, diaper rash creams, and bath products specifically formulated with gentle oat extracts and free of harsh chemicals. This division is marketed separately from Aveeno Skin Care, often positioned as a dermatologist-recommended solution for sensitive infant skin. In many markets, Aveeno Baby is the leading baby moisturizer brand.
Aveeno Baby Dermexa
Dermexa is a specialized sub-line under Aveeno Baby. It targets conditions like eczema-prone and highly sensitive skin. With colloidal oatmeal and ceramides, Dermexa products are designed for therapeutic use, offering relief from dryness and irritation. This product family enhances Aveeno’s clinical positioning in the pediatric dermatology category.
Aveeno Positively Radiant
Positively Radiant is Aveeno’s brightening and tone-correcting skincare line. It features cleansers, scrubs, moisturizers, and night creams designed to enhance skin radiance and reduce uneven skin tone. Using soy complex as a core ingredient, this sub-brand remains one of Aveeno’s most popular consumer lines, particularly in North America and Asia.
Aveeno Calm + Restore
Launched in recent years, Calm + Restore is formulated for ultra-sensitive skin. This sub-line uses oat extracts and soothing ingredients like feverfew to help reduce redness and irritation. It has expanded into moisturizers, serums, and facial mists, making Aveeno more competitive in the therapeutic skincare market.
Aveeno Clear Complexion
Clear Complexion focuses on acne-prone skin, offering cleansers, toners, and moisturizers infused with salicylic acid and soy. It is positioned as a hybrid of therapeutic skincare and cosmetic enhancement, helping prevent breakouts while evening skin tone.
Aveeno Daily Moisturizing
This sub-brand is one of Aveeno’s longest-running and most successful product lines. It includes body lotions, creams, and washes that are marketed for daily hydration and long-term skin barrier protection. It remains a cornerstone of Aveeno’s brand identity.
Aveeno Therapeutic Line
The therapeutic segment includes eczema therapy, anti-itch creams, and specialized hand/foot treatments. These products bridge the gap between cosmetic skincare and over-the-counter dermatological solutions. Recommended by dermatologists, this line strengthens Aveeno’s clinical credibility.
Aveeno Sun Care
Aveeno Sun Care includes sunscreens for adults and children, often formulated with mineral-based and broad-spectrum SPF protection. Unlike many cosmetic sunscreens, Aveeno emphasizes skin sensitivity and gentle application, targeting consumers who want both sun safety and skincare benefits.
Aveeno Hair Care (Aveeno Active Naturals)
Aveeno has expanded into hair care under its Active Naturals branding. The range includes shampoos, conditioners, and scalp treatments designed with oat extract and natural ingredients. The line positions itself against dandruff, scalp dryness, and sensitive scalp conditions while offering cosmetic benefits like shine and strength.
Aveeno Men’s Care
Although not as widely marketed globally, Aveeno Men’s Care includes facial cleansers, aftershaves, and moisturizers targeted at male consumers with sensitive skin. This line allows Aveeno to extend into the growing men’s skincare market.
Final Words
Aveeno has grown from a small oatmeal-based skincare line in 1945 to a global brand trusted by millions. When people ask who owns Aveeno, the answer today is Kenvue Inc., a consumer health giant that emerged from Johnson & Johnson. With strong shareholders, an experienced CEO, and a place in one of the world’s largest health product portfolios, Aveeno continues to thrive.
FAQs
Who owns the Aveeno brand?
Aveeno is owned by Kenvue Inc., a consumer health company that was spun off from Johnson & Johnson in 2023. Kenvue manages Aveeno along with other major brands like Neutrogena, Band-Aid, and Tylenol.
Is Aveeno owned by Johnson & Johnson?
No. Aveeno was originally part of Johnson & Johnson’s consumer health division, but it became part of Kenvue following the 2023 spin-off. Johnson & Johnson retained a small share of Kenvue after the separation, but Aveeno is now managed under Kenvue.
Who owns Aveeno and Kenvue?
Aveeno is owned by Kenvue Inc. Kenvue is a publicly traded company, so ownership is distributed among institutional investors, retail shareholders, and corporate insiders, with major stakes held by firms like Vanguard, BlackRock, and State Street.
Is Aveeno an Israeli company?
No. Aveeno was founded in the United States in 1945. It is an American brand with global distribution, but it is not Israeli.
Who makes Aveeno products?
Aveeno products are manufactured under Kenvue’s oversight. Major in-house manufacturing sites include Lititz (Pennsylvania, USA), Shanghai (China), and Bangkok (Thailand). The brand also uses contract manufacturers in various regions to meet local demand. All production follows strict quality and regulatory standards.
When was Aveeno founded?
Aveeno was founded in 1945 in the United States, originally as a small line of oat-based skincare products.
What is the country of origin of Aveeno?
Aveeno originated in the United States. Its formulations and brand philosophy were developed in the U.S., and it remains headquartered there under Kenvue.
Who bought Aveeno?
Aveeno was acquired by Johnson & Johnson in 1999 and remained part of its consumer health division until the 2023 spin-off, when ownership transferred to Kenvue.
Where are Aveeno products made?
Aveeno products are manufactured globally. Key facilities include Lititz, Pennsylvania (USA), Shanghai (China), and Bangkok (Thailand). Some products are also made by contract manufacturers in Europe, Asia, and other regions to meet local market needs.
What country is Aveeno made in?
Aveeno products are primarily made in the United States, with significant production also occurring in China, Thailand, and other regional contract manufacturing locations. The exact country may vary depending on the specific product and market.